Octreotide 50 µg IV Push: Dosing and Administration
For acute variceal hemorrhage, administer octreotide 50 µg as an intravenous push immediately upon suspicion of bleeding, followed by a continuous infusion of 50 µg/hour for 2–5 days. 1
Immediate Administration Protocol
Give the 50 µg IV bolus as soon as variceal bleeding is suspected—do not wait for endoscopy. 2, 1 This early initiation reduces 7-day mortality and transfusion requirements. 1
The bolus may be repeated within the first hour if bleeding persists. 1
Administer the IV push over 3 minutes per FDA labeling, though in emergency situations (e.g., carcinoid crisis) it may be given as a rapid bolus. 3
Continuous Infusion Following Bolus
Immediately start a continuous infusion at 50 µg/hour after the initial bolus. 1 This is critical because octreotide's duration of action is limited—a single IV bolus produces a reduction in portal pressure similar in magnitude and duration to somatostatin (approximately 1 hour), necessitating continuous infusion for sustained therapeutic effect. 4
Continue the infusion for 2–5 days. 2, 1 In compensated cirrhosis (Child-Pugh A or B) with no active bleeding on endoscopy, a 2-day course is reasonable. 1 Recent evidence suggests 24-hour infusions may be non-inferior to 72-hour infusions in preventing rebleeding. 5
Preparation and Compatibility
Dilute octreotide in 50–200 mL of sterile isotonic saline or dextrose 5% in water for infusion over 15–30 minutes, or administer undiluted by IV push over 3 minutes. 3
Do not mix with Total Parenteral Nutrition (TPN) solutions—octreotide forms a glycosyl conjugate that decreases efficacy. 3
Inspect for particulates and discoloration before administration; discard if present. 3
Mandatory Adjunctive Therapies
Combine with ceftriaxone 1 g IV every 24 hours (up to 7 days) to reduce infection, rebleeding, and mortality. 1
Perform endoscopic variceal ligation within 12 hours once hemodynamically stable—octreotide is not monotherapy. 1 Octreotide as an adjunct to endoscopic ligation reduces rebleeding from 38% to 9% (relative risk 0.22). 6
Clinical Rationale: Why Octreotide is Preferred
Octreotide is the vasoactive drug of choice in the United States based on its superior safety profile. 2 It has a 2.39-fold lower overall adverse-event rate compared with terlipressin or vasopressin, with markedly fewer episodes of abdominal pain, chest pain, diarrhea, and hyponatremia. 1
Efficacy is comparable to terlipressin and somatostatin for mortality, hemostasis, and rebleeding outcomes. 1
Monitoring and Safety Considerations
Monitor blood glucose levels—octreotide can cause both hypoglycemia and hyperglycemia; adjust insulin dosing accordingly. 1
Watch for rare adverse events including bradycardia and pancreatitis. 1
In cirrhotic patients, octreotide's half-life is prolonged (2.4–4.8 hours vs. 1.7–1.9 hours in healthy subjects) and clearance is decreased. 4 However, standard dosing remains appropriate because the drug must be given by continuous infusion to maintain therapeutic effect.
Common Pitfalls to Avoid
Do not delay octreotide administration while awaiting endoscopy—immediate initiation improves outcomes. 1
Do not use octreotide as monotherapy—it must be combined with endoscopic treatment and antibiotics. 1
Do not extend infusion beyond 5 days unless specific clinical circumstances justify longer therapy. 1
Do not administer through the same line as TPN. 3